Puntos destacados de la investigación:

Los adultos con enfermedades cardíacas a los que se les recetó vitamina D en dosis personalizadas hasta llegar a los niveles en sangre considerados óptimos para la salud cardíaca (>40-80 ng/ml) presentaron una...

Research Highlights:

During the 6 months after treatment to restore a normal heart rhythm, adults with atrial fibrillation (AFib) who were randomly assigned to drink coffee every day were 39% less likely to have a recurrence of AFib compared to...

Research Highlights: Adults with atrial fibrillation and obesity/overweight (but no diabetes) who took the diabetes medication metformin after a rhythm correction procedure were more likely to stay free of AFib episodes for a year. Weight loss was not ...

Research Highlights:

Earlier blood transfusion after major surgery – when hemoglobin was below 10 g/dL rather than beow 7 g/dl - did not affect the risk of severe complications, such as death, heart attack, need for a heart procedure, kidney failure...

Research Highlights: Successful catheter ablation resulted in a low risk of stroke associated with atrial fibrillation (AFib), a type of irregular heart rhythm, according to an international study. Researchers said these findings may suggest that ...

Research Highlights: Standard care, which included medication for those eligible, was better than a promising minimally invasive procedure for people with irregular heart rhythms who had high stroke and bleeding risk. The procedure seals off a small ...

Research Highlights: A one-month course of dual clot-preventing therapy followed by a single clot-prevention medication for the remainder of the standard 12-month regimen in adults with atrial fibrillation (AFib) who received a coronary stent was as ...

Research Highlights: For people who have experienced a heart attack or stroke, or who are at high risk of one and need further cholesterol lowering, a new daily pill may be a more convenient yet similarly effective option to injectable therapies. The ...

Research Highlights:

Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes and no history of a prior heart attack or stroke, the PCSK9 inhibitor...

Research Highlights:  

In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by...